Abstract: Objective To investigate the efficacy and safety of rhendostatin（endostar） combined with platinumbased chemotherapy for advanced nonsmall cell lung cancer（NSCLC）. Methods Total of 69 advanced NSCLC inpatients were selected and divided into two groups： 33 patients treated with endostar plus platinumbased chemotherapy（combined group） and 36 patients treated with platinumbased chemotherapy alone（monochemotherapy group）. The response rate（RR）， disease control rate（DCR），time to progression（TTP）and side effects were evaluated. Results After two cycles of the treatment， the RR in combined group and monochemotherapy group were 27.3％ and 19.4％，respectively（P＞0.05），the DCR were 90.9％ and 86.1％（P＞0.05）. After four cycles of the treatment， the RR in combined group and monochemotherapy group were 13.0％ and 10.7％（P＞0.05），the DCR were 82.6％ and 50.0％（P＜0.05）. The median TTP were 6.5 months and 4.7 months for combined group and monochemotherapy group, respectively. The main side effects of two groups were nausea／vomiting，fatigue， bone marrow depression and so on. Leukopenia and granulopenia were predominant in bone marrow depression. The incedence rate of nodal tachycardia in combined group was higher than that in monochemotherapy group（P＜0.05）. Conclusion Endostar in combination with platinumbased chemotherapy for NSCLC patients was effective, which can improve the median TTP and the DCR after four cycles of chemotherapy. It is worth further study.